CPhI China Sees Growth Fueled by Region's Internationalization and Regulatory Reform

With recent regulatory reforms stimulating international interest in the region, Asia’s largest pharmaceutical event returns with CPhI & P-MEC China (#CPhIChina) – organized by UBM and UBM SINEXPO – will take place at the Shanghai New International Expo Center (SNIEC) next month (June 20-22). The event will be co-located with ICSE, InnoPack, BioPh, Labworld, NEX, EP & Clean Tech, FDF, P-Logi, and Excipients.   China remains a region with unmatched growth potential, and companies globally are attempting to capitalize on the plethora of investment opportunities that have arisen in recent years. Of these, the Marketing Authorization Holder (MAH) – which expedites time to market for many international companies – is currently fueling innovation, and the possibility that it may be nationally introduced this year is a driving force for international attendance at CPhI China.    Other sweeping reforms in clinical trials have helped to reduce costs and barriers for companies conducting R&D within China. In 2018, the total pharmaceutical sales in China is projected to be $158 billion. The expected growth in international attendance is proof that companies are now looking to get a share of the world’s second largest pharma economy.   CPhI China will welcome 45,000 attendees and 3,000 exhibitors from over 120 countries, representing a year-on-year increase of 8% and 20% respectively. In response to this, three new country pavilions from Russia, Brazil and Poland have been added ­– further strengthening the relationships between China and the rest of the world.   For the first time, the event will host an International Business Program This two-track, one-day conference has been shaped to serve two key audiences – the first track will tackle topics of interest to the international pharma community who are looking to expand to or within the Chinese market, and the second track will address the needs of Chinese companies who are looking to grow operations internationally. Spanning topics from biotech innovation to a more favourable regulatory environment, the International Business Programme will also provide an opportunity for networking.   China has the most pharma manufacturers in the world, with 6,500 companies producing 1,500 types of API. In recent years there has been a rapid growth of generics production in China – both in domestic and exports consumption –  and in order to supply the required ingredients CPhI China has introduced an excipients zone "PharmaExcipients". Additionally, a new dedicated Animal Health & Feed zone will also be launched in light of the growing population and moves toward improving living standards.   Official website: www.cphi.com/china